HERA: what is the future of the European pandemic preparedness response?

The COVID-19 pandemic has emphasised the need for a coordinated pan-European response to health emergencies. On Tuesday, 19 September, AmCham EU hosted a Plenary meeting to address the future of the European Health Emergency Preparedness and Response Authority (HERA) and the lessons that can be learned from the American Biomedical Advanced Research and Development Authority (BARDA).

News
24 Oct 2021
Healthcare
 HERA: what is the future of the European pandemic preparedness response?

The event kicked off with a panel on advancing transatlantic coordination in pandemic preparedness moderated by Emilia Valbum (3M), Vice-Chair, Healthcare Committee, AmCham EU. The conversation featured experts from Europe and the US including Tamara Weinger-Požar, Deputy Ambassador to the Permanent Representation of Slovenia; Karel Lannoo, Chief Executive, CEPS and Christopher Houchens, Director, Division of CBRN Countermeasures, BARDA. The panel centred around the need for an ambitious plan for HERA, the necessity to support research and development (R&D) as well as the role of industry.

It was followed by a keynote address delivered by Pierre Delsaux, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission. Mr Delsaux highlighted that HERA will look beyond institutions and old governance models and focus on ensuring further support for R&D. 

A link between HERA and BREDA will also be crucial to pandemic preparedness.With a need for better access to data, support from and to the industry as well as allocated funding, HERA can prove a valuable solution to the future of pandemic preparedness if it manages to touch on the entire lifecycle of medicines and work to ensure cross-border collaboration.

Watch Emilia Valbum and Karel Lannoo discuss the role of HERA and how businesses can support it

Related items

News
20 May 2026

Healthcare, competitiveness, innovation and simplification

Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation. 

The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment. 

The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains. 

Healthcare
Simplification
Read more
Read more about Healthcare, competitiveness, innovation and simplification
Position Paper
19 May 2026

Strengthening EU competitiveness through an adaptive MDR/IVDR framework

Healthcare
Read more
Read more about Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026

A global approach to strengthening Europe’s biotechnology ecosystem

Healthcare
Read more
Read more about A global approach to strengthening Europe’s biotechnology ecosystem